Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
This trial has been completed.
|Sponsor||Eisai Co., Ltd.|
|Start date||June 2013|
|End date||May 2015|
|Trial size||8662 participants|
|Trial identifier||NCT02162264, ART08T|
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
time frame: Baseline, Month 3, Month 6, and Month 12
Investigations on adverse events and adverse drug reactions
time frame: Baseline and Month 12
Male or female participants of any age.
Inclusion criteria: Patients diagnosed with Alzheimer's Disease and administered Aricept for the first time. Exclusion criteria: Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Call for more information